Avastin: a new hope for corneal transplant patients?

Article

Topical bevacizumab (Avastin) has shown excellent preliminary results and good topical tolerance when used in the prevention of corneal transplant failure.

Topical bevacizumab (Avastin) has shown excellent preliminary results and good topical tolerance when used in the prevention of corneal transplant failure, according to Jose Güell and Merce Morral, from Instituto de Microcirugìa Ocular (IMO) de Barcelona, Spain, speaking at "The endothelium: new surgical and medical concepts" symposium.

Irreversible immune rejection is one of the leading causes of corneal graft failure. Preoperative measures to prevent graft rejection aim to minimize the antigenic difference between the host and the donor tissues, while a careful and precise surgical technique including centration of the graft, optimal suturing and sound graft-host application may also contribute to the prevention of graft rejection.

In order to reduce deep stromal vascularization of the host cornea, Dr Güell is subconjunctivally injecting 0.1 mL of Avastin, beginning with its use under topical administration, and his results with the off-label agent have been promising so far.

Dr Güell advised that topical and systemic steroids remain the standard for the prevention of corneal graft rejection, while oral azathioprine, cyclosporine (CsA) and other immunosuppressive drugs such as FK506 and mycophenolate mofetil are also clinically used for prevention. Sustained release drug delivery systems (DDS) of CsA and FK506 have been developed to avoid systemic side effects while maintaining therapeutic levels in the anterior segment of the eye.

Dr Güell concluded that although there have been developments in the improvement of pharmacological strategies to prevent corneal transplant, further research is needed to find new agents with better efficacy and safety.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.